Karyopharm Therapeutics | KPTI - Zobowiązania





Zobowiązania Zmiana Data
AbbVie USD 43.1B 1.46B 2026-09
Abbott USD 16.15B 1.66B 2026-09
Amgen USD 23.23B 2.27B 2026-09
AstraZeneca USD 31.27B 286M 2026-09
BioCryst Pharmaceuticals USD 195.83M 13.02M 2026-09
Bristol-Myers Squibb USD 18.75B 94M 2026-09
Eli Lilly USD 47B 745M 2026-09
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
GlaxoSmithKline GBP 20.72B 814M 2026-09
Incyte USD 1.44B 125.72M 2026-09
J&J USD 55.46B 562M 2026-09
Karyopharm Therapeutics USD 117.3M 25.24M 2026-03
MacroGenics USD 108.82M 12.88M 2026-06
Merck USD 28.8B 1.07B 2026-09
Nektar Therapeutics USD 57.71M 4.17M 2026-03
Novartis USD 32.52B 777M 2026-09
Novartis USD 32.52B 1.15B 2026-09
Pfizer USD 31.73B 920M 2026-09
Regeneron Pharmaceuticals USD 6.2B 671.5M 2026-09
Roche Holding CHF 28.85B 846M 2026-06
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Takeda JPY 2.6T 161B 2026-09
Tectonic Therapeutic USD 10.37M 2.59M 2026-06
TG Therapeutics USD 268.49M 81.38M 2026-06
Ultragenyx Pharmaceutical USD 389M 38M 2026-09
Xencor USD 76.27M 5.6M 2026-09